Financials in USD. Standardized financial statements.
A compact view of how Cartesian Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.80M | $38.91M | $26.00M | $110.78M | $85.08M | $16.60M | $6.68M | $903,000 | $207,000 | $8.08M |
| Revenue Growth? | -92.8% | +49.6% | -76.5% | +30.2% | +412.6% | +148.6% | +639.4% | +336.2% | -97.4% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $2.04M | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $2.80M | $38.91M | $26.00M | $108.74M | $85.08M | $16.60M | $6.68M | $903,000 | $207,000 | $8.08M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +98.2% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $89.50M | $82.81M | $112.42M | $94.20M | $89.67M | $73.42M | $59.13M | $64.95M | $63.24M | $41.95M |
| Operating Income? | -$86.70M | -$43.90M | -$86.42M | $14.54M | -$4.60M | -$56.82M | -$52.45M | -$65.02M | -$63.78M | -$34.67M |
| EBITDA? | -$86.70M | -$75.99M | -$235.03M | $39.84M | -$5.16M | -$65.59M | -$51.80M | -$62.87M | -$63.37M | -$34.16M |
| Income Before Tax | -$139.50M | -$77.14M | -$238.71M | $34.77M | -$9.72M | -$68.88M | -$55.35M | -$65.34M | -$65.32M | -$36.21M |
| Income Tax Expense | -$9.19M | $287,000 | -$19.00M | -$609,000 | $15.97M | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$130.30M | -$77.42M | -$219.71M | $35.38M | -$25.69M | -$68.88M | -$55.35M | -$65.34M | -$65.32M | -$36.21M |
| EPS? | $-5.02 | $-2.99 | $-49.76 | $7.33 | $-6.74 | $-20.42 | $-36.46 | $-87.55 | $-95.94 | $-103.52 |
| Diluted EPS? | $-5.02 | $-3.29 | $-49.76 | $3.00 | $-6.60 | $-20.42 | $-36.46 | $-87.55 | $-95.94 | $-103.52 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality